You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes
  1. Arya M Sharma
  1. University of Alberta, Edmonton, Alberta, Canada
  1. Correspondence to: Dr Arya M Sharma, Li Ka Shing Building, Rm 1-116, 87th Avenue and 112th Street, Edmonton, Alberta, Canada T6G 2E1; amsharm{at}ualberta.ca

https://doi.org/10.1136/ebmed-2016-110402

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Libman IM, Miller KM, DiMeglio LA, et al., T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 2015;314:2241–50OpenUrlCrossRefPubMed.

    Context

    Weight gain in individuals with type 1 diabetes (T1D) is associated with an increase in other cardiovascular risk factors (eg, hypertension, dyslipidaemia) and increasing insulin resistance, often requiring higher doses of insulin to maintain adequate glycaemic control. The goal of the current study was to explore the use of metformin to improve glycaemic control in overweight and obese adolescents with T1D.

    Methods

    A total of 140 overweight or obese adolescents with T1D, treated with either an insulin pump or at least three daily injections of insulin, age of 12 to <20 years, HbA1c level of 7.5–9.9% and a body mass …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.